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Summary
The androgen receptor (AR) is essential for the growth of prostate cancer cells. Here, we report that tyrosine phosphorylation
of AR is induced by growth factors and elevated in hormone-refractory prostate tumors. Mutation of the major tyrosine
phosphorylation site in AR significantly inhibits the growth of prostate cancer cells under androgen-depleted conditions.
The Src tyrosine kinase appears to be responsible for phosphorylating AR, and there is a positive correlation of AR tyrosine
phosphorylation with Src tyrosine kinase activity in human prostate tumors. Our data collectively suggest that growth
factors and their downstream tyrosine kinases, which are elevated during hormone-ablation therapy, can induce tyrosine
phosphorylation of AR and such modification may be important for prostate tumor growth under androgen-depleted
conditions.Introduction
Prostate cancer is the second leading cause of cancer death
among men in Western countries. Patients with advanced pros-
tate cancer initially benefit from androgen-ablation therapy,
which leads to temporary tumor remission due to apoptosis of
androgen-sensitive tumor cells. However, recurrence of andro-
gen-independent tumors is inevitable for most patients and ren-
ders the conventional hormone therapy ineffective (Denmeade
and Isaacs, 2002). It has, therefore, become a focus of intensive
study to understand the mechanisms underlying the develop-
ment of hormone-refractory prostate cancer (Debes and Tindall,
2004; Feldman and Feldman, 2001). The androgen receptor
(AR), a member of the steroid hormone receptor family, is pri-
marily responsible for mediating the physiological effects of
androgens by binding to specific DNA sequences, known as an-
drogen response elements (AREs), which regulate transcription
of androgen-responsive genes (Heinlein and Chang, 2004). In-
creasingly, clinical findings demonstrate that a majority of an-
drogen-ablation therapy-resistant prostate cancers still express
AR and androgen-dependent genes, indicating that the AR-CANCER CELL 10, 309–319, OCTOBER 2006 ª2006 ELSEVIER INC. DOIsignaling pathway is functional in the absence of androgens or
in the presence of low levels of androgens (Culig et al., 2000).
Several independent studies also showed that AR is essential
for both hormone-sensitive and -refractory prostate cancer
(Chen et al., 2004; Zegarra-Moro et al., 2002).
Mutations and amplification of AR, alterations in protein ki-
nases, growth factors, and nuclear receptor coactivators have
all been proposed to modulate AR signaling and may, therefore,
play key roles in the development of androgen independence of
prostate cancer (Feldman and Feldman, 2001; Gelmann, 2002).
Mutations in the ligand-binding domain of AR are shown to
broaden the ligand-binding profile of the mutant receptor (Veld-
scholte et al., 1990; Zhao et al., 2000). However, the frequency
of AR mutation is generally low and probably only accounts for
less than 10%of the cases surveyed (Taplin et al., 2003). Upreg-
ulation of the enzymes involved in steroid synthesis in some
recurrent prostate tumors and activation of AR via the intracrine
mechanism have also been reported (Titus et al., 2005a). How-
ever, the tissue androgen levels did not correlate with clinical
prognosis (Titus et al., 2005b). Recently, the increased AR ex-
pression level was shown to associate with the developmentS I G N I F I C A N C E
Recurrent prostate cancer is resistant to commonly used hormonal therapy and is the major cause of patient death. Study of altered
signaling events in hormone-refractory prostate cancer cells will allow us to developmore effective regimens andmore reliable prog-
nosticmarkers. In this study, we show that the androgen receptor can be phosphorylated by tyrosine kinase Src and suchmodification
appears to be important for prostate cancer cell growth under low-androgenconditions.Our results suggest that the level of AR tyrosine
phosphorylation may serve as a diagnostic tool to predict patient outcome in response to hormone-ablation therapy and inhibition of
tyrosine phosphorylation of AR may be an effective intervention target for hormone-refractory prostate cancer.10.1016/j.ccr.2006.08.021 309
A R T I C L Eof resistance to antiandrogen therapy (Chen et al., 2004). The
cross-talk between growth factor and AR-signaling pathways
in prostate cancer cells has been well documented. The expres-
sion of several peptide growth factors, such as EGF/TGFa, IL-6,
and IGF-1, are reported to be elevated during progression to
hormone-refractory human prostate cancer (Bartlett et al.,
2005; Di Lorenzo et al., 2002; George et al., 2005; Krueckl
et al., 2004; Lorenzo et al., 2003). These autocrine/paracrine
factors can either induce the androgen-independent activation
of AR transcriptional activity or sensitize AR to low concentra-
tions of androgens (Culig et al., 1994; Gregory et al., 2004;
Ueda et al., 2002). A substantial body of literature suggests
that AR is regulated directly by phosphorylation. Several protein
kinases, including themitogen-activated protein kinase (MAPK),
Akt/PKB, cAMP-activated protein kinase A (PKA), and protein
kinase C (PKC), have been shown to modulate AR transcrip-
tional activity by phosphorylating serine or threonine residues
in AR or its coactivators, such as the transcriptional intermediary
factor 2 (TIF2) and the steroid hormone receptor coactivator 1
(SRC1) (Gregory et al., 2004; Lin et al., 2001; Ueda et al.,
2002; Yeh et al., 1999). The expression of erbB2/HER-2/neu,
a member of the EGF receptor family tyrosine kinases, is in-
creased in a subset of hormone-refractory LAPC4 xenografts
(Craft et al., 1999). Forced overexpression of erbB2 in andro-
gen-dependent prostate cancer cells promotes androgen-inde-
pendent growth (Craft et al., 1999; Yeh et al., 1999). In addition
to erbB2, several other non-receptor tyrosine kinases, including
Src, FAK, and Etk/BMX, have been implicated in activation of AR
transcriptional activity in response to nonsteroid stimuli such
as IL-6 and bombesin (Lee et al., 2001, 2004). It is also shown
that Src kinase is directly associated with AR upon androgen
treatment through a nongenotropic pathway (Kousteni et al.,
2001; Migliaccio et al., 2000). However, the mechanisms by
which these tyrosine kinases regulate AR transcriptional activity
in prostate cancer cells are not well understood yet.
Here, we report that AR is tyrosine phosphorylated in prostate
cancer cells in response to growth factors. Our data suggest
that growth factors and their downstream tyrosine kinases,
which are elevated during hormone-ablation therapy, can in-
duce tyrosine phosphorylation of AR and such modification
may contribute to androgen-independent activation of AR or
sensitize AR to low levels of hormone. Our findings provide
a mechanism by which hormone-refractory prostate cancer
cells continue to grow under androgen-depleted conditions.
Results
Elevated tyrosine phosphorylation of AR in hormone-
refractory prostate tumor xenografts
We observed that the level of tyrosine phosphorylation is sig-
nificantly increased in hormone-refractory prostate xenograft
tumors compared to their hormone-sensitive counterparts (Fig-
ure 1A). Interestingly, the AR protein immunoprecipitated from
hormone-refractory tumors could also be recognized by the
anti-phosphotyrosine antibody (Figure 1B), suggesting that AR
is tyrosine phosphorylated. Moreover, tyrosine phosphorylation
of AR was significantly increased in hormone-refractory tumors
compared to their hormone-sensitive counterparts (Figure 1B).
To find out which tyrosine kinasemight be responsible for the in-
creased AR tyrosine phosphorylation, we examined the activity310of a panel of tyrosine kinases, including erbB2, FAK, and Src.
We only consistently detected the elevated Src kinase activity
in all hormone-refractory samples while the protein level of Src
remained largely unchanged (Figure 1C).
Tyrosine phosphorylation of AR in prostate cancer cells
To test whether AR could be tyrosine phosphorylated in prostate
cancer cells in response to extracellular stimuli, we treated
LNCaP cells with several growth factors and hormones, respec-
tively. As shown in Figure 2A, all tested stimuli, except for DHT,
could induce tyrosine phosphorylation of AR in LNCaP cells
under our experimental conditions. We also showed that EGF
induced a transient tyrosine phosphorylation of AR in all tested
AR-positive prostate cancer cell lineswith similar kinetics, which
peaked at 5min and tapered by 30min (Figure 2B). Interestingly,
the EGF-induced AR tyrosine phosphorylation was concomitant
with the increased phosphorylation of Y416 of Src kinase (Fig-
ure 2C), an indicator of Src kinase activity, and was significantly
diminished by the selective Src kinase inhibitors PP2 and
SU6656 (Figure 2D), as well as the siRNA specific for Src (Fig-
ure 2E), suggesting that it is, at least partially, dependent on
Src kinase activity. Figure 2F shows that the constitutively
active SrcY527F could induce tyrosine phosphorylation of the
endogenous AR in LNCaP cells as well as the exogenous AR
in COS-1 cells, while the kinase-inactive mutant SrcK295M
failed to do so. These data together indicate that EGF-induced
AR tyrosine phosphorylation is mediated by Src kinase.
Figure 1. Increased tyrosine phosphorylation in hormone refractory prostate
tumor xenografts
A: Hormone-sensitive (HS) and refractory (HR) xenograft tumors were de-
rived as described in Experimental procedures. The tumor lysates were
immunoblotted with anti-phosphotyrosine (apY) antibody. The sample load-
ing was monitored by Coomassie Blue staining (bottom).
B: The immunoprecipitated AR was subjected to immunoblotting with the
antibodies indicated. The ratio of pY/AR is shown at the bottom. For each
group, HR is higher than HS (p < 0.05).
C: Immunoblot with anti-phospho-SrcY416(apSrc) to determine the Src
kinase activity.CANCER CELL OCTOBER 2006
A R T I C L EIdentification of AR tyrosine phosphorylation sites using
mass spectrometry
Our MS analysis revealed that AR was phosphorylated at multi-
ple tyrosine residues (Figure 3A). All detected tyrosine phos-
phorylation sites were exclusively present in the sample derived
from the cells expressing both AR and the active Src, suggesting
that phosphorylation of these sites is induced by Src kinase.
We substituted all identified tyrosine residues with a phenylala-
nine individually to test its effect on Src-induced tyrosine phos-
phorylation of AR. The mutation of Y534 appears to diminish the
Src-induced tyrosine phosphorylation most, suggesting that
Y534 is one of themajor phosphorylation sites (Figure 3B). Inter-
estingly, the alignment of AR sequences from various species
showed that Y534 is evolutionally conserved, suggesting that
Y534 may be of functional importance (Figure 3C). To further
characterize phosphorylation of AR Y534, we developed
Figure 2. Growth factors induce tyrosine phosphorylation of AR in prostate
cancer cells
A: Serum-starved LNCaP cells were treated with 100 ng/ml of EGF, heregulin-
b1 (HRG), interleukin-6 (IL-6), 10% (v/v) charcoal-stripped fetal bovine serum
(FBS), and 10 nM dihydrotestosterone (DHT) for 5 min. AR tyrosine phosphor-
ylation was determined as described in Figure 1B.
B: Prostate cancer cells were treated with EGF as in (A) for the time indi-
cated. The levels of AR tyrosine phosphorylation were determined as above.
C: Serum-starved LNCaP cells were treated with 100 ng/ml EGF for the time
indicated. The cell lysates were immunoprecipitated with anti-Src antibody
and followed by immunoblotting with anti-pSrc antibody.
D: LNCaP cells were pretreated with 10 mM PP2 or SU6656 (SU) for 30 min and
then treated with 100 ng/ml EGF for 5 min. The AR tyrosine phosphorylation
were detected as in (A).
E: LNCaP cells were infected with lenti-virus encoding siRNA specific for lucif-
erase (siCon) or for Src (siSrc). After serum-starvation, the infected cells were
treated with EGF for 5 min. The AR tyrosine phosphorylation was determined
as above. The total cell lysates were immunoblotted with anti-Src and anti-
actin antibodies.
F: SrcY527F or SrcK295M were transfected into LNCaP cells or cotransfected
with AR into COS-1 cells; the AR tyrosine phosphorylation was detected as in
Figure 2A. The total cell lysates were also immunoblotted with anti-pSrc and
anti-Src antibodies, respectively.CANCER CELL OCTOBER 2006a phosphospecific antibody, anti-pARY534. The specificity of
this antibody was validated by various assays described in the
Supplemental data (Figures S4 and S5). We found that AR
Y534 phosphorylation was significantly increased in hormone-
refractory tumor xenografts compared to their hormone-sensi-
tive counterparts (Figure 3D). Subsequently, we performed
immunohistochemical (IHC) analysis on human prostate tissue
arrays by using the antibodies specific for AR, pARY534 and
pSrcY416, respectively. As summarized in Table 1 and Fig-
ure S7, the phospho-ARY534 staining was detected in all hor-
mone-refractory samples examined. The mean immunostaining
scores for pARY534 and pSrcY416 staining in hormone-refrac-
tory samples are significantly higher than those in hormone-
naive and normal samples (p < 0.0001). Although 57.14% of
normal and 47.25% of hormone-naive samples in our surveys
show weak pSrcY416 staining, only less than 24.14% of both
normal and hormone-naive samples are pARY534 positive. It
is possible that Src kinase activity may have to reach a certain
threshold level in the cells in order to allow pARY534 to become
detectable, as phosphorylation of AR is a transient and dynamic
event. Our statistical analysis also revealed a positive correlation
between the levels of phospho-AR and phospho-Src in the sam-
ples examined, suggesting that the increase in AR tyrosine
phosphorylation could be, at least in part, due to the elevated
Src kinase activity. Figure 3E shows the representative fields
of our prostate tissue arrays. The increase in ARY534 phosphor-
ylation in a human hormone-refractory tumor was also con-
firmed by the Western blot analysis (Figure 3F). Taken together,
these data suggest that the increase in AR tyrosine phosphory-
lation and Src kinase activity is associated with prostate cancer
progression.
Tyrosine phosphorylation regulates AR
transcriptional activity
Figure 4A shows that EGF induced an approximately 4-fold ac-
tivation of the ARR2-Luc reporter and this effect was blocked by
the pretreatment of cells with the selective Src kinase inhibitor
SU6656, suggesting that it is mediated by Src kinase. Figures
4B–4D show that SrcY527F induced the activities of the PSA
promoter, the ARR2 promoter, and an artificial promoter com-
posed of five consecutive copies of ARE, suggesting that Src
may directly modulate AR-mediated transcriptional activity. Fur-
thermore, EGF-induced AR transcriptional activity could not be
blocked by Casodex (Figure 4E), while the DHT-induced AR
transcriptional activity was. These data suggest that the effect
of EGF is independent of androgen in LNCaP cells. However,
the AR siRNA could block both the EGF-induced AR transcrip-
tional activation and PSA production, suggesting that the effect
of EGF is mediated by AR (Figure S8).
Figure 4F shows that the substitution of Y534 with phenylala-
nine significantly inhibited the transcriptional activity of AR in-
duced by EGF or SrcY527F, while the mutant responded to
DHT at the concentrations of 1–10 nM as well as the wild-type
AR did in COS-1 cells (Figure 4G), suggesting that phosphoryla-
tion of Y534may not be essential for AR activation under normal
physiological conditions. However, at low levels of DHT (0.05–
0.5 nM), the Y534F mutation significantly diminished the tran-
scriptional activity of AR (Figure 4G). Combination of low doses
of androgens and EGF could synergistically enhance the tran-
scriptional activity of ARwt, compared to either one alone (Fig-
ure 4H) and such effect was dramatically blocked by ARY534F311
A R T I C L EFigure 3. Identification of AR tyrosine phosphory-
lation sites
A:Mass spectrometry identified AR tyrosine phos-
phorylation sites (in bold and underlined).
B:COS-1 cells were transfected with the plasmids
as indicated. After serum-starvation, the cells
were lysed and AR tyrosine phosphorylation
was detected as in Figure 1B.
C: Alignment of AR protein sequences to show
that Y534 is evolutionarily conserved.
D: Pooled protein extracts from HR and HS tumor
xenografts (Figure 1) were immunoprecipitated
with anti-AR antibody, followed by immunoblot-
ting with anti-pARY534 (apAR) antibody. The fold
changes of the pAR/AR ratio compared to HS
sample were shown (bottom).
E: Representative fields of normal prostate tissue,
hormone-naive (HN), and hormone-refractory
(HR) human prostate tumor arrays immunohisto-
chemically stained with anti-pAR, anti-pSrc, and
anti-AR antibodies as indicated.
F: The lysates of a HR tumor, the pooled HN
tumors, and the pooled normal prostate tissues
were immunoblotted with the indicated anti-
bodies. The fold change in AR tyrosine phosphor-
ylation was labeled as in (D).mutation. Taken together, these data suggest that phosphoryla-
tion of Y534 is required for the growth factor-induced ligand-in-
dependent activation of AR, as well as for the optimal activation
of AR induced by low levels of androgen.
Consistent with the reporter assays, we found that both EGF
and SrcY527F could induce an increase in PSA protein level,
which could be blocked by SU6656 (Figure S9). These data fur-
ther confirmed the effects of EGF and Src kinase on AR tran-
scriptional activation. To test whether phosphorylation of Y534
is required for PSA expression, we replaced the endogenous
AR with the mutant AR carrying Y534F mutation by using the312‘‘AR replacement’’ strategy described in Figure 4I, which al-
lowed us to assess the contribution of a specific mutation in
AR to its biological activity under the conditions close to the nat-
ural milieu. The replacement of the endogenous AR in LNCaP
cells was achieved by knocking down the endogenous AR via
the siRNA specific for AR and simultaneously introducing back
an exogenous codon-switched AR (ARcs) cDNA that contains
three silent mutations in the siRNA target sequence. Introduc-
tion of Y534F mutation on the ARcs backbone allowed us to ex-
press the mutant ARcs-Y534F in cells expressing the siRNA tar-
geting the endogenous AR. The replacement of AR was carriedCANCER CELL OCTOBER 2006
A R T I C L ETable 1. Association of phosphorylation of AR and Src with prostate cancer progression
pARY534
Nucleus Cytoplasm pSrcY416
Group Main 6 SE N (+%) Mean 6 SE N (+%) Mean 6 SE N (+%)
Normal 0.6449 6 0.2822 46(10.87) 0.1033 6 0.0723 46(4.35) 1.5691 6 0.2708 35(57.14)
HN 1.2893 6 0.2647 87(24.14) 1.1303 6 0.2422 87(23.00) 1.6960 6 0.2265 91(47.25)
HR 5.8190 6 0.4051 18(100) 6.0278 6 0.2548 18(100) 4.9352 6 0.5019 18(94.44)
p Value <0.0001 <0.0001 <0.0001
The immunostaining scores (mean6 standard error [SE]) for pARY534 (both in the cytoplasm and nucleus) and pSrcY416 in normal epithelium, hormone-naive
(HN), and refractory (HR) prostate tumor foci are summarized. N represents the number of the cases with the percentage of the positive staining cases (+%)
in the parentheses. A total of 151 cases were analyzed for pARY534 staining and 144 cases for pSrcY416 staining. The statistical differences between HR and HN
in immunoreactivity with each antibody were determined by Wilcoxon rank sum test. The immunoreactive scores of HR are significantly higher than those of
HN tumors (*p < 0.0001). The Pearson correlation coefficient r of the immunoreactive scores between total pAR (cytoplasm plus nucleus) and pSrc is 0.32538
(p < 0.0001).out by coinfection of the lenti-viruses encoding the ARcs and the
siRNA specific for AR at >95% efficiency in all prostate cancer
cells tested. We replaced the endogenous AR with the ARcs-
wt or ARcs-Y534F in LNCaP cells and then examined the effects
of Y534F mutation on the PSA production induced by DHT and
EGF. Figure 4J shows that the PSA production of the cells
expressing the ARcs-Y534F mutant was significantly reduced
in comparison to that of the cells expressing the ARcs-wt in re-
sponse to EGF or to low levels (0.01 and 0.1 nM) but not high
levels (1 and 10 nM) of DHT. Taken together, these results
suggest that Y534 phosphorylation of AR is required for PSA
production in prostate cancer cells stimulated by low levels
of DHT or by growth factors under the androgen-depleted
conditions.
Tyrosine phosphorylation regulates AR translocation
Translocation of AR from the cytoplasm into the nucleus is re-
quired for AR to exert its transcriptional activity in cells, we
therefore examined whether phosphorylation of Y534 could
influence AR nuclear translocation in prostate cancer cells. Im-
munofluorescence microscopy revealed that SrcY527F could
induce the nuclear translocation of AR in LNCaP cells in the
absence of androgens (Figure 5A). The SrcY527F-promoted nu-
clear translocation of AR was also observed in PC-3 cells ex-
pressing the exogenous wild-type AR. As shown in Figure 5B,
the nuclear translocation of AR was only detected in the cells
expressing the active Src (arrows), while AR was primarily in
the cytosol of the cells lacking the active Src (arrowheads). How-
ever, the majority of the ARY534F mutant remained in the cyto-
sol and failed to translocate into the nucleus even in the pres-
ence of the active Src. Cell fractionation also showed that
SrcY527F could significantly increase the level of ARwt but
not ARY534F in the nuclear fraction (Figure 5C). As a positive
control, 10 nM DHT dramatically increased the levels of AR in
the nuclear fraction, regardless of Y534 mutation. These data
suggest that phosphorylation of Y534 may be required for the
Src-promoted nuclear translocation of AR under androgen-
depleted conditions.
AR tyrosine phosphorylation regulates prostate cancer
cell growth under androgen-depleted conditions
Figure 6A shows that growth of C-81 cells in androgen-depleted
medium was significantly increased by EGF, and this effect can
be blocked by Src siRNA or AR siRNA. This suggests that EGF
is driving AR-dependent cell growth under androgen-depletedCANCER CELL OCTOBER 2006condition and Src kinase is required for this process. Moreover,
the Src siRNA dramatically inhibited the growth of C-81 and
CWR-R1 cells in castrated male nude mice (Figures 6B and
6C), and such inhibition coincided with diminished ARY534
phosphorylation, while phosphorylation of MAPK remained
largely unchanged (Figure 6D), implying that Src kinase may be
required for the growth of hormone-refractory prostate cancer
cells in castrated mice possibly by phosphorylating AR.
In addition, we replaced the endogenous ARwith the ARcs-wt
or ARcs-Y534F in an AR-positive androgen-independent pros-
tate cancer cell line, CWR-R1, as described in Figure 4I. The ef-
fects of Y534F mutation on cell proliferation in the androgen-
depleted medium were examined. Similar to what we observed
in C-81 cells (Figure 6A), EGF can increase the growth of CWR-
R1 cells, and this effect can be inhibited by the siRNA for either
AR or Src (Figure 7A). Moreover, reintroducing of the exogenous
wild-type AR(ARcs-wt) back to CWR-R1 cells could partially
rescue the growth inhibition caused by the AR siRNA, while
the ARcs-Y534F mutant failed to do so. Furthermore, in cas-
trated male mice, growth of LNCaP tumor xenografts express-
ing SrcY527F is significantly increased compared to the vector
control (Figure 7B), and such effect was significantly blocked
when the endogenous AR was replaced with ARcs-Y534F (Fig-
ure 7C), suggesting that the active Src can promote prostate
cancer cell growth under androgen-depleted conditions and it
is dependent on ARY534 phosphorylation. To further examine
whether phosphorylation of Y534 is required for the growth of
hormone-refractory prostate cancer cells, the endogenous AR
in hormone-resistant CWR-R1 cells was replaced with the
ARcs-wt or ARcs-Y534F. The growth of the cells was examined
in the castrated male nude mice. Figure 7E shows that the sizes
of the tumors expressing the ARcs-Y534F mutant were signifi-
cantly smaller than those of the tumors expressing the ARcs-
wt, suggesting that the integrity of Y534 is important for the
growth of CWR-R1 in the castrated male nudemice. In contrast,
these cells grew equally well in the intact male mice, regardless
of Y534mutation (Figure 7F). Taken together, our results demon-
strated that Src-induced ARY534 phosphorylation is important
for prostate tumor growth under androgen-depleted conditions.
Tyrosine phosphorylation is required for the recruitment
of AR to the chromatins
Because AR regulates gene expression primarily through bind-
ing to AREs in the promoter/enhancer region of its target genes,
we examined whether tyrosine phosphorylation of AR could313
A R T I C L EFigure 4. Modulation of AR transcriptional activ-
ity by tyrosine phosphorylation
A: LNCaP cells were transfected with ARR2-Luc
reporter. After serum-starvation, the cells were
pretreated with or without 2 mM SU6656 (SU) for
30 min then treated with 50 ng/ml EGF for 16 hr
before the luciferase activity was measured.
The results were presented as the mean relative
light units (RLU) 6 SD of the triplicate samples.
B–D: LNCaP cells were transfected with PSA-Luc
(B), ARR2-Luc (C), or 5xARE-Luc (D), along with
the vector control, SrcY527F or SrcK295M, as
indicated after serum-starvation overnight, the
luciferase activity was determined as in (A).
E: LNCaP cells were transfected with ARR2-Luc.
After serum-starvation, the cells were pretreated
with 10 mM Casodex (CA) for 30 min then treated
with 50 ng/ml EGF or 1 nM DHT for 16 hr before the
luciferase activity was determined as in (A).
F: COS-1 cells were transfected with ARR2-Luc
along with ARwt or ARY534F; the EGF or
SrcY527F-induced luciferase activity was deter-
mined.
G: COS-1 cells cultured in the medium with char-
coal-stripped serum were transfected with ARwt
or ARY534F along with the ARR2-Luc and then
treated with DHT at the indicated doses for 24
hr. The luciferase activity was determined as in
(A).
H: COS-1 cells were transfected with ARwt or
ARY534F, along with the ARR2-Luc. After serum-
starvation, the cells were treated with 50 ng/ml
EGF and DHT at different doses as indicated.
The luciferase activity was determined.
I: AR-replacement strategy. LNCaP cells were
coinfected with the lenti-virus encoding AR
siRNA, and the FLAG-tagged wild-type AR
(ARwt), FLAG-tagged codon-switched wild-
type AR (ARcs-wt), or FLAG-tagged codon-
switched Y534F mutant (ARcs-Y534F). At 48 hr
postinfection, the AR proteins were examined
by immunoblotting with anti-AR or anti-FLAG
antibodies as indicated (right panel).
J: Following AR replacement, the infected
LNCaP cells were incubated in the medium con-
taining 5% charcoal-stripped serum with differ-
ent doses of DHT or incubated in the serum-free
medium with 10 ng/ml EGF for 2 days. The levels
of PSA and pAR from the immunoblots were nor-
malized by calculating the ratios of PSA/actin
and pAR/AR, respectively. The changes in fold
compared to the control (0 nM DHT or EGF-
treated ARwt) were shown (bottom).modulate its recruitment to those of PSA and KLK2 by using a
chromatin immunoprecipitation (ChIP) assay. We first tested
whether EGF could induce AR recruitment to the promoter/en-
hancer region of PSA and KLK2 in LNCaP cells with the DHT
treatment as a positive control. Figure 7G shows that DHT could
induce the AR occupancy of the ARE sites located in both the
promoter and the enhancer regions of PSA and KLK2 genes
as reported previously (Shang et al., 2002). However, EGF treat-
ment only promoted AR binding to the promoter ARE site(s) but
not the enhancer ARE site(s) of these genes, suggesting that the
differential recruitments of AR to distinct AREs could occur in
response to different stimuli. Pretreatment of LNCaP cells with
SU6656 completely abolished the EGF-induced AR occupancy
on the promoter sites. Using the AR-replacement strategy, we
also found that EGF failed to induce the recruitment of the
ARY534F mutant to the promoter sites of both genes314(Figure 7H). Taken together, these results suggest that Src-
induced Y534 phosphorylation is required for EGF-induced
recruitment of AR to the ARE-containing promoter/enhancers.
In addition, the EGF-induced transcription of endogenous AR
target genes, including PSA, KLK-2, and POV-1, was inhibited
by Y534F mutation as determined by quantitative real-time
RT-PCR (Figure S10). This further supports our hypothesis
that growth factor-induced AR tyrosine phosphorylation may
regulate AR target gene transcription under androgen-depleted
conditions.
Discussion
Growth factors have long been proposed to play a role in the
regulation of AR transcriptional activity, especially under the
androgen-depleted conditions. However, the mechanisms byCANCER CELL OCTOBER 2006
A R T I C L Ewhich nonsteroid peptide growth factors modulate AR activity
are not well understood, though several studies have shown
that it may be mediated by direct phosphorylation of AR or
its cofactors through a kinase cascade involving some serine/
threonine kinases, as reported previously. We have observed
that the overall level of tyrosine phosphorylation is significantly
increased in hormone-refractory human prostate tumor xeno-
grafts derived from castrated male mice, suggesting that tumor
cells may utilize the autocrine/paracrine factors activating tyro-
sine kinases to compensate for loss of androgens. Furthermore,
we have provided biochemical evidence that AR is tyrosine
phosphorylated in response to several growth factors, including
EGF, heregulin, and IL-6. These factors are known to be either
highly expressed in prostate tissues or elevated in prostate
tumors. EGF is one of most abundant growth factors present
in prostate tissues and promotes the survival and growth of
prostate epithelial cells. IL-6 is negatively regulated by andro-
gens and upregulated upon castration in murine models (Bellido
et al., 1995). Several independent studies showed that IL-6 can
Figure 5. Regulation of AR nuclear translocation by tyrosine phosphoryla-
tion
A: LNCaP cells were transfected with SrcY527F. After serum-starvation, im-
munofluorescence confocal microscopy was carried out by costaining cells
with anti-AR (red) and anti-pSrc (green) antibodies as described (scale bar,
5 mm). Arrow: SrcY527F-positive cell; arrowhead: SrcY527F-negative cell.
B: PC-3 cells were first infected with lenti-virus encoding ARwt or ARY534F.
The infected cells were transiently transfected with SrcY527F or SrcK295M
and stained as in (A).
C: The infected and transfected PC-3 cells from (B) were serum-starved
overnight and treated with or without 10 nM DHT for 1 hr. The cell fraction-
ation was carried out as described in Supplemental data. Equal amounts
of cytoplasmic (C) and nuclear (N) fraction were immunoblotted. HSP90
and PARP were used as markers of the cytoplasmic and nuclear fractions,
respectively.CANCER CELL OCTOBER 2006also activate AR transcriptional activity in the absence of andro-
gens and promote androgen-independent growth of human
prostate cancer cells in mouse xenograft models (Lee et al.,
2003b; Steiner et al., 2003). Therefore, these factors and their
downstream tyrosine kinases may account for, at least in part,
the increased tyrosine phosphorylation level of AR and other
proteins in hormone-refractory tumor xenografts.
Several independent attempts were made to identify the
phosphorylation sites of AR, and only phosphoserines or phos-
phothreonines were uncovered in these studies (Gioeli et al.,
2002; Zhou et al., 1995). The nature of rapid and transient tyro-
sine phosphorylation of AR induced by growth factors may
make it difficult to be captured by the conventional metabolic la-
beling methods and therefore may explain why tyrosine phos-
phorylation of AR was not detected by the previous studies.
We have identified multiple tyrosine phosphorylation sites in
AR induced by the Src kinase in vivo by the MS analysis. Substi-
tution of Y534, one of the major phosphorylation sites induced
by Src kinase, with phenylalanine has profound effects on AR-
mediated transcription and growth. Our findings suggest that
Src-induced phosphorylation of Y534 in AR may play an impor-
tant role in the survival/growth of prostate cancer cells under an-
drogen-depleted conditions. At this time, we still do not know
whether phosphorylation of ARY534 alone is sufficient to confer
Figure 6. Src kinase inhibition leads to growth attenuation under androgen-
depleted conditions
A: C-81 cells were infected with the lenti-virus encoding the siRNA specific
for luciferase (control), AR (siAR), or Src (siSrc). The cell growth was moni-
tored using WST-1 assay. *Control + EGF versus Control at 48 hr and 72 hr
(p < 0.01); **Control + EGF versus siAR + EGF/siSrc + EGF at 48 and 72 hr (p
< 0.01). The data were expressed as the average of normalized triplet sam-
ples (mean 6 SD). The levels of AR and Src in these cells were detected by
immunoblotting at 48 hr postinfection (right panel).
B–D: C-81 (B) and CWR-R1 (C) cells were infected with the lenti-virus encod-
ing the siRNA specific for luciferase (SiCon) or Src (SiSrc). At 48 hr postinfec-
tion, the cells were injected into the left and right flank of the castrated male
nude mice, respectively, and growth of the tumors were examined as de-
scribed. *p < 0.01. The result represents the mean tumor volume 6 SE (n =
5 mice/group). Immunoblots of Src, phospho-ERK1/2 (pERK1/2), ERK1/2,
and pAR in the CWR-R1 tumors (D).315
A R T I C L EFigure 7. Effect of AR tyrosine phosphorylation
on prostate cancer cell growth under andro-
gen-depleted conditions
A: CWR-R1 cells were infected with the lenti-virus
encoding AR siRNA (siAR), Src siRNA (siSrc), ARcs-
wt, and ARcs-Y534F as indicated. The cell growth
was monitored using WST-1 assay. *siAR + ARcs-
wt + EGF versus siAR + EGF at 48 and 72 hr (p <
0.01); **siAR + ARcs-Y534F + EGF versus siAR +
EGF at 48 and 72 hr (p > 0.05); ***siAR + ARcs-wt +
EGF versus siAR + ARcs-Y534F + EGF at 48 hr and
72 hr (p < 0.05). The data were expressed as the
average of normalized triplet samples (mean 6
SD). The levels of AR in these cells were detected
by immunoblotting at 48 hr postinfection as in
Figure 4I (right panel).
B–D: LNCaP cells were infected with lenti-virus
encoding SrcY527F and vector control (B); the
AR in LNCaP cells were replaced with ARcs-wt
or ARcs-Y534F and coinfected with lenti-virus en-
coding SrcY527F(C). At 48 hr postinfection, the
cells were injected into castrated male SCID
mice. The result represents the mean tumor vol-
ume6 SE (n = 5 mice/group). *p < 0.05. The levels
of pAR, AR, pSrc, and Src in the cells were de-
tected by immunoprecipitation and immuno-
blotting at 48 hr postinfection (D).
E and F: After AR replacement, the CWR-R1 cells
expressing ARcs-wt (solid) or ARcs-Y534F (open)
were injected into the castrated (E) and intact
(F) male nude mice. The result represents the
mean tumor volume 6 SE (n = 5 mice/group).
*p < 0.01. Inset, Western blots of FLAG-AR and
pAR of the CWR-R1 xenograft tumors.
G and H: LNCaP cells were treated for 1 hr with
100 ng/ml EGF, 10 nM DHT, or pretreated with
SU6656 (SU) for 30 min and followed by EGF treat-
ment (SU + EGF). The binding of AR to the pro-
moter (P) or the enhancer (E) of PSA or of KLK2
or to an irrelevant control region (C) was ana-
lyzed by ChIP assay using anti-AR antibodies
(G). Following AR replacement, the LNCaP cells
were treated with 100 ng/ml EGF for 1 hr, and
the AR binding to the promoter of PSA or of
KLK2and an irrelevant control region (C) was an-
alyzed by ChIP using anti-FLAG antibodies (H).
PCR products from input (1), immunoprecipita-
tion with control antibody (2), and with anti-AR/
FLAG antibody (3) were resolved on agarose
gels.androgen-independence, as the ARY534D/E mutants failed to
promote prostate cancer cell growth under androgen-depleted
conditions (Z.G. and Y.Q., unpublished data). One explanation
could be that the D/E mutation may not faithfully mimic the tyro-
sine phosphorylation of AR. Given that AR is phosphorylated at
multiple tyrosine residues, it is also possible that multiple phos-
phorylation events may act synergistically and are required for
Src-induced activation of AR. Currently, we are actively investi-
gating the functional significance of other identified tyrosine
phosphorylation sites and their possible contribution to hor-
mone-independent growth of prostate cancer cells.
In this report, we showed that non-receptor tyrosine kinase
Src activity is elevated in hormone-refractory prostate tumors.
Although Src was identified as an oncogene in animal models316several decades ago, the evidence of mutation or overexpres-
sion of Src family kinases in human prostate cancer is scant,
while it has been shown that Src kinase is overexpressed in
breast and colon cancer patients (Biscardi et al., 2000; Yeat-
man, 2004). Given that Src kinases can be activated by a variety
of extracellular stimuli, including growth factors and matrix pro-
teins, it is likely that upregulation of its kinase activity by the de-
regulated autocrine/paracrine factors or microenviroment may
be amore commonmechanism by which Src kinases contribute
to human malignancies. It is possible that some other tyrosine
kinases activated by Src, such as FAK or Etk/BMX, may also
be involved in the induction of AR tyrosine phosphorylation in
a subset of tumors where these kinases are overexpressed
due to the heterogeneous nature of prostate cancers. This isCANCER CELL OCTOBER 2006
A R T I C L Esupported by our observation that the level of phospho-AR is
also elevated in the Etk transgenic mouse prostate (B.D. and
Y.Q., unpublished data). In addition, overexpression of erbB2
has been reported in a subset of hormone refractory tumors.
However, under our experimental conditions, the erbB2 inhibitor
AG879 has little effect on EGF-induced ARY534 phosphoryla-
tion, suggesting that erbB2 may exert its effect via a distinct
pathway (e.g., MAPK pathway), as suggested by previous stud-
ies, other than phosphorylating ARY534.
It is still unclear how tyrosine phosphorylation modulates AR
transcriptional activity. One possible scenario is that tyrosine
phosphorylation of AR may induce conformational change
of AR, which mimics the ligand-binding effect in the absence of
androgens or facilitates the ligand binding in the presence of
extremely low level of androgens. This is corroborated by our
observation that Y534 mutation diminishes the Src-promoted
nuclear translocation of AR. Phosphorylation may also act as
a conformation switch to control the transition of AR from the in-
active to the active conformation, which allows AR to dissociate
from the negatively regulatory proteins (e.g., HSP90) upon being
tyrosine phosphorylated and subsequently dimerize and/or as-
sociate with the nuclear import machinery complex in the ab-
sence of androgens. Future studies to identify the associated
proteins with AR in the active conformation will allow us to un-
derstand the mechanisms by which Src promotes AR nuclear
translocation.
One issue for debate on the growth factor-induced androgen-
independent activation of AR transcriptional activity is that
growth factor (e.g., EGF or IL-6) alone in general can only induce
a few-fold increase of AR transcriptional activity in the serum-
free medium, which seems to be negligible in comparison to
the magnitude of the optimal induction by androgens. However,
based on the studies of the dose response of LNCaP cells to an-
drogen in tissue culture (Berns et al., 1986; Olea et al., 1990), low
levels of androgens (0.01–0.1 nM) promote while high levels of
androgens (1–100 nM) inhibit LNCaP cell proliferation. The in-
duction of AR transcriptional activity in tissue culture by low
levels of androgens is also in the range of a few-fold increase,
which is comparable to that induced by growth factors. Thus, it
is possible that a few-fold increase of AR transcriptional activity
may be sufficient for regulating a subset of AR-regulated genes
that are required for promoting the survival/growth of prostate
cancer cells. In addition, the differential recruitment of AR to
the AREs present in the different chromatin context by growth
factors may preferentially turn on a subset of AR-regulated sur-
vival/growth-promoting genes. Therefore, it is possible that
autocrine/paracrine loops, which generate high local concentra-
tions of various growth factors, may be sufficient to maintain AR
transcriptional activity and promote the survival and growth of
these cells under the androgen-depleted conditions.
On the other hand, at this time, we cannot exclude the possi-
bility of the presence of an extremely low level of androgens or
some androgen-like factors in the reagents used in our experi-
ments. As a matter of fact, no absolutely androgen-free circum-
stance exists under physiological/pathological conditions, since
the level of residual androgens in patients treated with the abla-
tion therapy might not be as low as we previously thought. In
spite of that, DHT alone does not induce appreciable tyrosine
phosphorylation of AR in LNCaP cells in the serum-freemedium;
a low level of AR tyrosine phosphorylation is detectable in nor-
mal mouse prostate tissues (Z.G. and Y.Q., unpublished data)CANCER CELL OCTOBER 2006as well as in human benign prostate tissue samples. Thus, tyro-
sine phosphorylation of ARmay also play a role in modulation of
AR activity in the normal prostate gland, though such modula-
tion may not be essential for AR-mediated transcription regu-
lated by androgens at normal physiological levels as suggested
by our data. However, upon androgen ablation, the dependency
on ARY534 for its transcriptional activity may become pro-
nounced. This is supported by our observations that both integ-
rity of ARY534 and Src kinase activity are required for AR-medi-
ated transcriptional activity at low levels of androgens and
prostate cancer cell growth in castrated mice, and AR tyrosine
phosphorylation is significantly increased in hormone-refractory
tumors, as detected by our anti-pARY534 antibody. These find-
ingsmay be of clinical importance, as hormone-refractory tumor
cells appear to utilize the autocrine/paracrine factors activating
tyrosine kinases to promote AR transcriptional activity after the
androgen-ablation therapy. Therefore, the combinatory therapy
with the inhibitors targeting at the tyrosine kinases (e.g., Src and
Etk), whose activities are elevated after the ablation therapy,
may be a more effective regimen for advanced prostate cancer.
In this study, we showed that tyrosine phosphorylation of AR
is elevated in human hormone-refractory prostate cancer. It is
noteworthy that over 65% (13 out of 20) of the pARY534-positive
hormone-naive samples are of Gleason sum greater than 8. Pre-
vious studies suggested that patients having poorly differenti-
ated tumors with high Gleason sum are likely resistant to hor-
monal therapy in nature, and approximately 15% of prostate
cancer patients will not respond to hormone manipulation. It
has yet to be determined whether the pARY534 antibody could
be used for identifying these patients, at least in part, prior to
hormonal therapy. If so, the status of AR tyrosine phosphoryla-
tionmay be used as a parameter to predict the patient outcomes
in response to androgen-ablation therapy in the future.
Experimental procedures
Phosphorylation site mapping by mass spectrometry
To map the phosphorylation sites of AR induced by Src, COS-1 cells were
cotransfected with expression vectors encoding AR and SrcY527F. AR pro-
tein was immunoprecipitated and then purified by SDS-PAGE. The AR pro-
tein was visualized by Coomassie Blue staining and excised. The gel slice
was subjected to digestion with trypsin (Promega) overnight at 37C. The
peptides were extracted and analyzed as described previously (Yu et al.,
2004). The raw MS/MS data were searched by using SEQUEST (ThermoFin-
nigan, San Jose, CA) against a database consisting of the androgen receptor
protein sequence. Phosphorylation sites were determined by allowing a dy-
namic modification of 79.966 Da to tyrosine, serine, and threonine residues.
The identified fully tryptic phosphopeptides were further examined by man-
ually inspecting the MS/MS spectra to confirm identification of the correct
peptide sequence and the correct sites of phosphorylation.
In vitro cell growth assay and in vivo tumor growth
in the xenograft models
At 48 hr post-lentivirus infection, cells were seeded at the density of 4 3 103
cells/well in the 96-well plate with phenol red-free RPMI 1640 medium con-
taining 5% charcoal-stripped serum and allowed to attach to the plate over-
night. The cells were then treated with or without 10 ng/ml EGF for the indi-
cated time. Growth was monitored using WST-1 (Roche) according to the
manufacturer’s instructions. The data were expressed as the average of nor-
malized triplet samples (mean 6 SD). The Student’s t test was used to com-
pare the statistic differences between groups. The tumor growth in the SCID/
nude mice were carried out as described previously (Craft et al., 1999; Long
et al., 2000). All procedures involving animals were approved by IACUCof the
University of Maryland. To obtain the hormone-refractory tumors used in the
study, tumor cells were allowed to grow in ten intact male mice for 4–10317
A R T I C L Eweeks, respectively, to reach the sizes around 500 mm3. The mice were then
divided into two groups. One group was sacrificed and tumors were col-
lected; another group were castrated and the tumor remission followed
within a few weeks after castration. Subsequently, the tumors were allowed
to regrow back to the size around 500 mm3. Two or three independent hor-
mone-refractory tumors were collected and subjected to the subsequent
analysis along with their hormone-sensitive counterparts.
Immunohistochemical analysis
Two intermediate-density prostate tissue arrays were prepared by the NYU
Cooperative Prostate Cancer Tissue Resource and consisted of a total 156
cases (four cores per case) including 18 hormone-resistant (HR) and 18 hor-
mone-naive (HN) transurethral resection (TURP) specimens of prostate from
patients with clinically advanced prostate cancer, 73 cases of HN prostate
cancer tissue (Gleason sum 6–10) from the radical prostatectomy specimens
of patients with clinically localized prostate cancer, and 47 cases of non-tu-
mor-containing tissue from patients with benign prostatic hypertrophy. The
determination of HN and HR was as follows: (1) patients who had earlier un-
dergone surgical orchiectomy or medical hormone-suppressive therapy at
least 6 months prior to the procedure were considered as HR; (2) patients
who did not receive hormonal therapy prior to the TURP were considered
as HN. Tissue specimens were from the archival paraffin block inventory
of the NYU Cooperative Prostate Cancer Tissue Resource. All cases upon
collection into the resource (under an IRB-approved protocol) had repeat
pathology characterization of tissues and review of medical records.
The Vectastain Elite ABC Kit (Vector Laboratories) was used for immuno-
histochemical staining according to the protocol recommended by the
manufacturer. Immunostaining was evaluated manually and graded using a
two-score system based on intensity score (IS) and proportion score (PS)
as described (Harvey et al., 1999). The immunoreactive score for each
case was quantified by the average of four cores. The statistical analyses
were carried out by using the SAS version 9.0 statistics software.
Supplemental data
The Supplemental Data for this article can be found online at http://www.
cancercell.org/cgi/content/full/10/4/309/DC1/.
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